STOCK TITAN

Prothena Corporation plc Ordinary Shares - $PRTA STOCK NEWS

Welcome to our dedicated page for Prothena Corporation plc Ordinary Shares news (Ticker: $PRTA), a resource for investors and traders seeking the latest updates and insights on Prothena Corporation plc Ordinary Shares stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Prothena Corporation plc Ordinary Shares's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Prothena Corporation plc Ordinary Shares's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.41%
Tags
conferences earnings
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.51%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
22.71%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.09%
Tags
conferences earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.13%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Prothena Corporation plc Ordinary Shares

Nasdaq:PRTA

PRTA Rankings

PRTA Stock Data

1.23B
38.28M
12.44%
100.76%
12.04%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
DUBLIN 2

About PRTA

prothena corporation plc (nasdaq: prta) is a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapy programs for the potential treatment of diseases that involve amyloid or cell adhesion. the company focuses on therapeutic monoclonal antibodies directed specifically to disease-causing proteins, and its antibody-based product candidates target a number of potential indications, including al amyloidosis (neod001), parkinson’s disease and other related synucleinopathies (prx002), and novel cell adhesion targets involved in psoriasis and other inflammatory diseases (prx003). our lead program, neod001, is in a global phase 3 registration clinical trial – the vital amyloidosis study. there is also an on-going phase 1/2 trial. prx002 is in a phase 1 multiple ascending dose clinical trial, and prx003 is in a phase 1 single ascending dose clinical trial. prothena’s elite team has a recognized track record both f